94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Ingrid Dubois-Vedrenne1
Olivier De Henau1†Virginie Robert1†Francina Langa2
Joaquim Javary1
Diana Al Delbany1
Olivier Vosters1†
Edgar Angelats-Canals1
Maxime Vernimmen1Souphalone Luangsay1,3†
Valérie Wittamer1
Marc Parmentier1*- 1IRIBHM and Welbio, Université Libre de Bruxelles, Brussels, Belgium
- 2Centre d'Ingénierie Génétique Murine (CIGM), Institut Pasteur, Paris, France
- 3Ogeda S.A., Gosselies, Belgium
A Corrigendum on
Expression of Bioactive Chemerin by Keratinocytes Inhibits Late Stages of Tumor Development in a Chemical Model of Skin Carcinogenesis
by Dubois-Vedrenne, I., De Henau, O., Robert, V., Langa, F., Javary, J., Al Delbany, D., et al. (2019). Front. Oncol. 9:1253. doi: 10.3389/fonc.2019.01253
Joaquim Javary was not included as an author in the published article.
The corrected Author Contributions Statement appears below.
Author Contributions
VW and MP designed the study. ID-V, OD, and VR performed most experiments. JJ, DA, MV, OV, EA-C, and SL contributed to experiments. FL generated the K5-chemerin mouse lines. ID-V wrote the initial draft. MP supervised the study, acquired funding, and wrote the final draft. All authors edited the manuscript.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: chemerin, CMKLR1, ChemR23, chemical carcinogenesis, squamous cell carcinoma
Citation: Dubois-Vedrenne I, De Henau O, Robert V, Langa F, Javary J, Al Delbany D, Vosters O, Angelats-Canals E, Vernimmen M, Luangsay S, Wittamer V and Parmentier M (2020) Corrigendum: Expression of Bioactive Chemerin by Keratinocytes Inhibits Late Stages of Tumor Development in a Chemical Model of Skin Carcinogenesis. Front. Oncol. 10:977. doi: 10.3389/fonc.2020.00977
Received: 15 May 2020; Accepted: 18 May 2020;
Published: 23 June 2020.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2020 Dubois-Vedrenne, De Henau, Robert, Langa, Javary, Al Delbany, Vosters, Angelats-Canals, Vernimmen, Luangsay, Wittamer and Parmentier. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Marc Parmentier, bXBhcm1lbnRAdWxiLmFjLmJl
†Present address: Olivier De Henau, iTeos Therapeutics, Gosselies, Belgium
Virginie Robert, Ambiotis SAS, Toulouse, France
Olivier Vosters, Europe Hospitals, Brussels, Belgium
Souphalone Luangsay, Roche Pharmaceutical Research and Early Development, Basel, Switzerland